3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
3
CNS
3
Myeloid
2
Lymphoid
2
Genitourinary
2
Gastrointestinal
2
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
4
Pheochromocytoma
2
Paraganglioma
2
Thymoma
1
Sarcoma, Synovial
1
Recurrence
1
Osteosarcoma
1
Neuroblastoma
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Glioma
1
Glioblastoma
1
Esthesioneuroblastoma, Olfactory
1
Ependymoma
1
EGFR-Mutated Non-Small-Cell Lung Carcinoma
1
Carcinoid Tumor
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
tipifarnib
1
olaparib
1
lutetium Lu 177 dotatate
1
entinostat
1
Tamoxifen
1
Surveys and Questionnaires
1
Radiotherapy
1
Photochemotherapy
1
Fentanyl
1
Doxorubicin
1
Dihematoporphyrin Ether
1
Cisplatin
1
90Y-octreotide, DOTA-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ependymoma
×
olaparib
×
Endocrine
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled